MTEP hydrochloride - CAS 1186195-60-7
Catalog number: 1186195-60-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Glutamate, the major excitatory neurotransmitter in the brain, acts on both ionotropic and metabotropic glutamate receptors. Excessive metabotropic glutamate receptor (mGluR) transmission has been linked to epilepsy, ischemia, pain, anxiety, and depression. Eight subtypes (1-8) and multiple splice variants of the mGluR have been identified and grouped based on their pharmacological properties. Group I mGluRs (subtypes 1 and 5) activate the phosphatidyl inositol pathway, while Group II (2 and 3) and Group III (4, 6, 7, and 8) inhibit adenylyl cyclase. MTEP is a negative allosteric modulator of the mGlu5a receptor subtype (Ki = 42 nM; IC50 = 110 nM). MTEP at 0.3 mg/kg produces antidepressant effects in several rodent models of depression. It also demonstrates neuroprotective potential by preventing excitotoxic neuronal damage when administered through either intrahippocampal or intraperitoneal injection. Additionally, MTEP demonstrates an anxiolytic-like phenotype in rodent models similar to that of benzodiazepines while lacking undesirable sedative and addictive effects.
Publictions citing BOC Sciences Products
  • >> More
3-((2-Methyl-1,3-thiazol-4-yl)ethyn-yl)pyridine hydrochloride; MTEP
1.Interactions of CB1 and mGlu5 receptor antagonists in food intake, anxiety and memory models in rats.
Varga B1, Kassai F, Gyertyán I. Pharmacol Biochem Behav. 2012 Dec;103(2):425-30. doi: 10.1016/j.pbb.2012.09.016. Epub 2012 Sep 28.
CB(1) receptor antagonists proved to be effective anti-obesity drugs, however, their depressive and anxiogenic effects became also evident. Finding solution to overcome these psychiatric side effects is still in focus of research. Based on the available clinical and preclinical results we hypothesized that the combination of CB(1) and mGlu(5) receptor antagonisms may result in a pharmacological intervention, where the anxiolytic mGlu(5) receptor inhibition may counteract the anxiogenic psychiatric side effects of CB(1) antagonism, while CB(1) antagonism may ameliorate the memory impairing effect of mGlu(5) receptor antagonism. Further, the two components will synergistically interact in blocking food-intake and reducing obesity. For testing the interaction of mGlu(5) and CB(1) receptor antagonism MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pridine; SIB-1757, 6-methyl-2-(phenylazo)-3-pyridinol)] (mGlu(5) antagonist) and rimonabant [(5-(4-Chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide)hydrochloride] (CB(1) antagonist) were used.
2.Activation of lateral hypothalamic mGlu1 and mGlu5 receptors elicits feeding in rats.
Charles JR1, Duva MA2, Ramirez GJ3, Lara RL3, Yang CR4, Stanley BG5. Neuropharmacology. 2014 Apr;79:59-65. doi: 10.1016/j.neuropharm.2013.10.033. Epub 2013 Nov 9.
Metabotropic glutamate receptors (mGluRs) have been popular drug targets for a variety of central nervous system (CNS) disease models, ranging from seizures to schizophrenia. The current study aimed to determine whether mGluRs participate in lateral hypothalamic (LH) stimulation of feeding. To this end, we used satiated adult male Sprague-Dawley rats stereotaxically implanted with indwelling bilateral LH guide cannulas to determine if injection of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (ACPD), a broad mGluR group I and II agonist, would elicit feeding. Administration of 100 nmol ACPD induced feeding with a short latency. Similarly, unilateral LH injection of the selective mGluR group I agonist (S)-3,5-dihydroxyphenylglycine (DHPG) elicited significant feeding beginning 60 min postinjection and continuing until 4 h postinjection. Administration of the mGluR5 agonist, (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) produced a smaller delayed feeding response.
3.Environmental condition alters amphetamine self-administration: role of the MGluR₅ receptor and schedule of reinforcement.
Arndt DL1, Johns KC, Dietz ZK, Cain ME. Psychopharmacology (Berl). 2015 Oct;232(20):3741-52. doi: 10.1007/s00213-015-4031-x. Epub 2015 Jul 28.
RATIONALE: Evidence suggests that differential rearing influences the function of a receptor subtype critical for maintaining glutamate homeostasis. Maintaining homeostatic glutamatergic function may be an important protector against drug abuse.
4.Non-competitive metabotropic glutamate 1 receptor antagonists block activity of slowly adapting type I mechanoreceptor units in the rat sinus hair follicle.
Cahusac PM1, Mavulati SC. Neuroscience. 2009 Oct 20;163(3):933-41. doi: 10.1016/j.neuroscience.2009.07.015. Epub 2009 Jul 28.
Previous studies suggested that Group I metabotropic glutamate (mGlu) receptors play a role in mechanotransduction processes of slowly adapting type I mechanoreceptors. Using an isolated rat sinus hair follicle preparation we tested a range of compounds. Surprisingly, only non-competitive mGlu1 receptor antagonists produced profound and long-lasting depression of mechanically evoked firing. 6-Amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-alpha]benzimidazole-2-carboxamide hydrochloride (YM-298198) had an IC(50) of 8.7 muM (95% CI 5.7 to 13.2 microM), representing the most potent known blocker of type I mechanoreceptors. The derivative 6-amino-N-cyclohexyl-3-methylthiazolo[3,2-alpha]benzimidazole-2-carboxamide hydrochloride (desmethyl YM-298198) had a comparable potency. Another compound 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylate ethyl ester (CPCCOEt) had a similar depressant effect, although it was less potent with an approximate IC(50) of 100 microM.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mGluR Products

CAS 1445605-23-1 Lu AF21934

Lu AF21934
(CAS: 1445605-23-1)

Lu AF21934 is a selective and brain-penetrating positive allosteric modulator (PAM) of mGlu4 receptors (IC50= 500 nM) on the harmaline-induced tremor and other ...

(CAS: 932737-65-0)

FITM is a potent mGlu1 inhibitor (Ki = 2.5 nM) with great selectivity that does not disrupt mGlu5.

CAS 1127498-03-6 JNJ-40411813

(CAS: 1127498-03-6)

JNJ-40411813 is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC50 of 147 nM.

CAS 802906-73-6 RG7090

(CAS: 802906-73-6)

RG7090 is a negative modulator of metabotropic glutamate receptor subtype 5 (mGluR5; GRM5).

CAS 635318-11-5 LY404039

(CAS: 635318-11-5)

LY-404,039, also known as pomaglumetad, is an amino acid analog drug that acts as a highly selective agonist for the metabotropic glutamate receptor group II su...

CAS 97240-79-4 Topiramate

(CAS: 97240-79-4)

Topiramate is a kainate GluR5 receptor antagonist,originally used as an anticonvulsant.

CAS 96206-92-7 MPEP

(CAS: 96206-92-7)

MPEP is a selective mGlu5 receptor antagonist with IC50 of 36 nM, exhibiting no appreciable activity at mGlu1b/2/3/4a/7b/8a/6 receptors.

CAS 232605-26-4 Bay 36-7620

Bay 36-7620
(CAS: 232605-26-4)

BAY 36-7620 elective mGlu1 receptor non-competitive antagonist (IC50 = 0.16 μM) with inverse agonist activity.

CAS 524924-76-3 Methoxy-PEPy

(CAS: 524924-76-3)

Methoxy-PEPy is a potent and highly selective mGlu5 receptor antagonist.

CAS 56-85-9 L-Glutamine

(CAS: 56-85-9)

L-Glutamine is one of the 20 amino acids encoded by the standard genetic code.

CAS 1311385-32-6 LY2979165

(CAS: 1311385-32-6)

LY2979165 is a mGlu2 agonist, which is a novel potent agent that is used as anti-depressants.

CAS 693288-97-0 CPPHA

(CAS: 693288-97-0)

CPPHA is a selective positive allosteric modulator of mGluR5 receptor. It is thought to act at a novel allosteric site and potentiates mGlu5 responses by a mech...

CAS 2018282-44-3 BMT-145027

(CAS: 2018282-44-3)

BMT-145027 is a potent mGluR5 PAM without inherent agonist activity with an EC50 of 47 nM. BMT-145027 is a non-MPEP site PAM to demonstrate in vivo efficacy.

CAS 1161205-04-4 VU 0361737

VU 0361737
(CAS: 1161205-04-4)

CAS 57653-26-6 Fenobam

(CAS: 57653-26-6)

Fenobam is a potent, selective, noncompetitive glutamate mGluR5 receptor antagonist. It displays inverse agonist properties. It blocks mGluR5 constitutive activ...

CAS 871362-31-1 CTEP

(CAS: 871362-31-1)

CTEP is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor (IC50=2.2 nM), showing >1000-fold selectivity over other mGlu receptor...

CAS 201943-63-7 LY341495

(CAS: 201943-63-7)

Very selective nanomolar potent antagonist for group II mGlu receptors. Also a relatively potent antagonist for group III mGlu receptors at high nanomolar to lo...

CAS 543906-09-8 Mavoglurant

(CAS: 543906-09-8)

Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist (IC50=30 nM), as a a selective non-competitive antagonist.

CAS 872363-17-2 Dipraglurant

(CAS: 872363-17-2)

Dipraglurant is a mGlu5 receptor negative allosteric modulator. It is currently in phase II for the treatment of dyskinesia in Parkinson's disease.

CAS 1246086-78-1 VU 0364439

VU 0364439
(CAS: 1246086-78-1)

Chemical Structure

CAS 1186195-60-7 MTEP hydrochloride

Quick Inquiry

Verification code

Featured Items